Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident Heart Failure

Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review


  1. Clinical Outcomes Related to Background Diuretic Use and New Diuretic Initiation in Patients With HFrEF

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  2. Relationship of Dapagliflozin With Serum Sodium: Findings From the DAPA-HF Trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  3. NT-proBNP and ICD in Nonischemic Systolic Heart Failure: Extended Follow-Up of the DANISH Trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  4. Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk in DAPA-HF

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  5. Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection Fraction

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  • J David Smeijer
  • Jeroen Koomen
  • Donald E Kohan
  • John J V McMurray
  • George L Bakris
  • Ricardo Correa-Rotter
  • Fan-Fan Hou
  • James L Januzzi
  • Dalane W Kitzman
  • Daniel M Kolansky
  • Hirofumi Makino
  • Vlado Perkovic
  • Sheldon Tobe
  • Hans-Henrik Parving
  • Dick de Zeeuw
  • Hiddo J L Heerspink
Vis graf over relationer

BACKGROUND: The endothelin receptor antagonist atrasentan reduced the risk of kidney failure in patients with type 2 diabetes mellitus and chronic kidney disease (CKD) in the SONAR (Study of Diabetic Nephropathy with Atrasentan) trial, although with a numerically higher incidence of heart failure (HF) hospitalization.

OBJECTIVES: The purpose of this study was to assess if early changes in B-type natriuretic peptide (BNP) and body weight during atrasentan treatment predict HF risk.

METHODS: Participants with type 2 diabetes and CKD entered an open-label enrichment phase to assess response to atrasentan 0.75 mg/day. Participants without substantial fluid retention (>3 kg body weight increase or BNP increase to >300 pg/mL), were randomized to atrasentan 0.75 mg/day or placebo. Cox proportional hazards regression was used to assess the effects of atrasentan vs placebo on the prespecified safety outcome of HF hospitalizations.

RESULTS: Among 3,668 patients, 73 (4.0%) participants in the atrasentan and 51 (2.8%) in the placebo group developed HF (HR: 1.39; 95% CI: 0.97-1.99; P = 0.072). In a multivariable analysis, HF risk was associated with higher baseline BNP (HR: 2.32; 95% CI: 1.81-2.97) and percent increase in BNP during response enrichment (HR: 1.46; 95% CI: 1.08-1.98). Body weight change was not associated with HF. Exclusion of patients with at least 25% BNP increase during enrichment attenuated the risk of HF with atrasentan (HR: 1.02; 95% CI: 0.66-1.56) while retaining nephroprotective effects (HR: 0.58; 95% CI: 0.44-0.78).

CONCLUSIONS: In patients with type 2 diabetes and CKD, baseline BNP and early changes in BNP in response to atrasentan were associated with HF hospitalization, highlighting the importance of natriuretic peptide monitoring upon initiation of atrasentan treatment. (Study Of Diabetic Nephropathy With Atrasentan [SONAR]; NCT01858532).

TidsskriftJACC. Heart failure
Udgave nummer7
Sider (fra-til)498-507
Antal sider10
StatusUdgivet - jul. 2022

Bibliografisk note

Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.

ID: 79371020